Treating Schizophrenia in the Era of COVID-19
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia
2
Evenamide for Treatment-Resistant Schizophrenia: Initiation of ENIGMA-TRS 2 Phase 3 Clinical Study
3
Data Fails to Show Significant Change in Cognition and Function With Oral Semaglutide for Early Alzheimer Disease
4
FDA Accepts NDA for TRN-257 for Treatment of Narcolepsy and Idiopathic Hypersomnia
5
